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Abstract  
Introduction: To leverage functionality and clinical relevance into understanding systems 
biology, one needs to understand the pathway of the genetic effects on risk factors/disease through 
intermediate molecular levels, such as metabolomics. Systems approaches integrate multi-omic 
information to find pathways to disease endpoints and make optimal inference decisions.  
Method: Here, we introduce a multi-stage approach to integrate causal networks in 
observational studies and GWAS to facilitate mechanistic understanding through identification of 
pathways from the genome to risk factors/disease via metabolomics. The pathways in causal networks 
reveal the underlying relationships behind observations, which do not play a significant role in more 
traditional correlative analyses, where one variable at a time is considered.  
Results: We identified a causal network over the metabolomic level using the genome directed 
acyclic graph (G-DAG), to systematically assess whether variations in the genome lead to variations in 
triglyceride levels as a risk factor of cardiovascular disease. We found LRRC46 and LRRC69 harboring 
loss-of-function mutations have significant effect on two metabolites with direct effects on triglyceride 
levels. We also found pathways of FAM198B and C6orf25 to triglycerides through indirect paths from 
metabolites.  
Conclusion: Integrating causal networks with GWAS facilitates mechanistic understanding in 
comparison to one-variable-at-a-time approaches due to accounting for relationships among 
components at intermediate molecular levels. This approach is complementary to experimental studies 
to identify efficacious targets in the age of big data sets. 
 
Keywords: integrated systems approach, metabolomic causal network, Bayesian network, Mendelian randomization, 
triglycerides, loss of function mutation  
 
Introduction  
Genome-wide association studies (GWAS) and recently whole genome sequence (WGS) studies have been 
widely conducted in humans with the goal of identifying genetic factors predictive of disease. Despite the extensive 
discovery of those studies, much of the genetic contributions to complex phenotypes remain unexplained. Furthermore, 
conclusions of noticeable numbers of genetic studies have not been in agreement with clinical presentation in an 
individual patient 1. A key attribute for increasing confidence in potential clinical validity of gene variation with risk 
factors and disease end-points will be the development of assays with more direct mechanistic link. It is biologically 
meaningful that with a chronic systemic disease, molecular signals more proximal to the disease process may serve as 
strong biomarkers 2 and as a result, identify more stable pathways from the genome to disease risk factors and end-
points. Therefore, integration of information in orthogonal data from different omics provides mechanistic understanding 
and has attracted attentions 3.  
The metabolome is the end product of gene-environment interactions, Figure 1, and may be risk factors for future 
disease or biomarkers of current disease processes  4 5 6. Metabolites can serve as intermediate phenotypes for genomic 
studies to illuminate mechanisms underlying of a specific SNP/gene, identify biological pathways linking the genome 
to disease, and discover valuable clinical biomarkers 2. Therefore, integration of genetics and metabolomics holds 
potential for elucidating mechanisms for deciphering chronic disease. 
 
Figure 1. Metabolomics an integrated readout of many biological processes, such as genetic, transcriptomic, and 
proteomic variation, can characterize and recognize metabolic signatures of common chronic diseases.  
Integration of data at different omics is challenging due to having largescale datasets and relationship between 
components. Most of the attempts at large scales are based on one component at a time that do not take into account the 
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underlying relationships among components. Identification of causal networks based on Mendelian randomization and 
Bayesian graphical modeling is an established approach to discover relations among components of interest and reduce 
the risk of false positive discovery 8 9. In this study, we introduce an integrative approach to identify pathways from the 
genome to risk factors via metabolomics. To provide insights into underlying relationships among metabolites, a 
metabolomic causal network is identified by leveraging genome information from using the G-DAG algorithm10 
(genome directed acyclic graph). Using the metabolomic causal network, we determine how genome variation leads to 
variability in risk factor levels through metabolomics. This approach reduces the spurious identification in comparison 
to one-metabolite-at-a-time approaches due to revealing relation among metabolites and identifying confounders at 
metabolomic level. To the best of our knowledge so far, no one has systematically analyzed metabolomic data to identify 
pathways from the genome to risk factor/disease via metabolomic networks. Here, we introduce a system approach to 
this aim and present an application.  
 
Mendelian randomization/instrumental variable: Genetic markers have been employed in multiple studies to prevent 
the analyses being confounded 8 11. This is called Mendelian randomization or instrumental variable (IV) approach which 
seeks to find a randomized experiment embedded in an observational study (Yazdani et al., 2014). IV approaches are 
based on some assumptions, see for example 13. To hold the assumptions, the conventional approach is to find a genetic 
variant strongly associated with the variable of interest which may not be pragmatic at largescale metabolomic studies, 
see for example 14. To overcome this challenge, the G-DAG algorithm generates strong IVs through extracting 
information from multiple variants and allocates multiple independent IVs to each metabolite, to make overall IVs even 
stronger, Figure 2.  
 
Figure 2. Visualization of some features of the G-DAG algorithm. White nodes indicate generated IVs from multiple 
SNPs. Brown nodes indicate metabolites. The aim is identification of underlying relationship between the 
metabolites (browns) using the IVs (whites). 
The G-DAG algorithm combines this IV approach with Bayesian graphical modeling to identify a causal network over 
metabolites in observational studies. Using a metabolomic causal network, the approach below identifies pathways from 
the genome to risk factor/disease:  
 
1. Underlying relationships among metabolites: Instead of analyzing an individual metabolite at a time, we identify a 
metabolomic causal network to infer underlying metabolomic relationships in an observational study. In the 
metabolomic network, nodes represent metabolites linked by directed edges which represent cause and effect 
relationships based on Mendelian principles. These relationship/pathway identification has multiple advantages, such 
as determining the role of each metabolite and its influence on the other metabolites as well as distinguishing 
intervention targets from disease predictors 15.   
 
2. Metabolites with direct effect on risk factors/disease: Using the identified relationships among metabolites and 
application of structural equation modeling, we find metabolites with direct effect on risk factors (Yazdani et al., 
2016a). Given the set of metabolites with direct effect on the risk factors, the rest of metabolites in the study do not 
have a significant effect on the risk factors. Therefore, a focus on the set of metabolites with direct effect on a risk 
factor is sufficient to know about the risk factor from the metabolomic level. 
 
3. Gene-metabolite relationship: Through genome analysis with metabolites as phenotypes, we investigate gene-
metabolite relationships. 
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After taking these steps, we can focus on genetic variations that exert their function through metabolomics which bridge 
gene effects to clinical end points. These pathways are identified after overcoming co-linearity at metabolomic level (step 
1). Therefore, they facilitate mechanistic understanding and generate more efficacious hypotheses for clinical experiment.  
 
Case Study  
We focused on plasma triglycerides as a risk factor of cardiovascular disease. For the genome analysis, we focused 
on loss-of-function (LoF) mutations  defined as sequence changes caused by single nucleotide variants or small insertions 
and deletions, which are predicted to result in a non-viable transcript or greatly truncated protein product 16.  
 
Study sample: Genomic data and serum metabolites were available on a subset of the Atherosclerosis Risk in 
Communities (ARIC) study 17, 2,479 African-American (range in age from 45-64 years) who were randomly sampled 
from Jackson, Mississippi field center. Focusing on participants from the same race and region, we assume to overcome 
environmental confounders which may affect on metabolites, such as population-to-population and regional dietary 
variations. In addition to metabolites and dense genetic marker data, multiple risk factor phenotypes related to health and 
chronic diseases including plasma triglycerides were measured.  
Metabolic profiling was completed in June 2010 carried out on fasting serum samples stored at -80 degrees 
centigrade since collection at baseline in 1986–1987. A total of 602 metabolites were detected and semiquantified by 
Metabolon Inc. (Durham, North Carolina) using an untargeted gas chromatography-mass spectrometry and liquid 
chromatography-mass spectrometry-based quantification protocol 18. Metabolites were excluded on the basis of 3 criteria. 
First, more than 50% of the samples had missing values. Second, they had unknown chemical structures. Third, the 
metabolites or any transformation of them did not follow normal distribution. After this assessment, a total of 122 named 
metabolites were included in the study. Some information, such as the name and pathway of these metabolites are provided 
in Supplementary, Table S6.  
Common single nucleotide polymorphisms (SNPs) were genotyped using the Affymetrix platform (version 6.0) 
consisting of 1,034,945 common variants spread across the genome. Variation across this data set was extracted and used 
to identify a metabolomic causal network.  
Sequencing data of the protein-coding regions of the genome were also available; the annotations were captured 
by NimbleGen’s VCRome2.1 (Roche NimbleGen), and the captured exons were sequenced using Illumina HiSeq 2000. 
The Burrows-Wheeler Aligner was used to align sequences to the hg19 reference genome 19. Allele calling and variant 
call file construction were performed using the Atlas2 suite 20 (Atlas-SNP and Atlas-Indel). Variants were annotated using 
ANNOVAR 21 according to the reference genome GRCh37 and National Center for Biotechnology Information Reference 
Sequence.  
 
Identification of the metabolomic network: We identified the metabolomic network over 122 metabolites using the G-
DAG algorithm (Yazdani et al., 2016b). The G-DAG algorithm first utilizes hierarchical clustering to measure linkage 
disequilibrium using square of correlation 22 and determine proxies from SNPs that are nearly perfectly correlated (>0.80) 
with others. Information from 1,034,945 SNPs scattered across the genome was extracted to generate multiple IVs. Over 
all of the chromosomes, 788 IVs were selected to identify the causal network. Minimizing the average structural Hamming 
distance (Tsamardinos et al., 2006), the tuning parameter was fit at level 0.001. In total 353 genome IVs remained in the 
model to identify the metabolomic network over 122 metabolites. The output is depicted in Figure 4 a. The employed IVs 
explained variation in the metabolites even up to 96%; although this result varied depending on the number of IVs 
influencing a specific metabolite. More details of the G-DAG algorithm are provided in Supplementary.  
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a.        b.  
Figure 4. a. Identified metabolomic causal network using the G-DAG algorithm established in Mendelian randomization 
and Bayesian network modeling. Pale nodes represent genome IVs which explained even up to 96% variation in 
metabolites. Orange nodes represent metabolites. b. The metabolite relationships from Figure 4a without 
depicting the IVs. Each link represents relationship between two corresponding metabolites when effects from 
other metabolites are excluded. Directions are identified based on Mendelian principles using genome IVs. 
Note that the genome IVs were employed as a tool to identify the underlying metabolomic relationships. Therefore, after 
building the network, we focus on the metabolomic relationships, Figure 4b. In the metabolomic network, directions are 
identified robustly using Mendelian principles and represent cause and effect relationships. For further analysis of the 
metabolomic network, such as modules and individual properties of the metabolites, see 24. 
 
Metabolite-triglyceride pathways: An extension of the G-DAG algorithm 25 was conducted to identify metabolites with 
direct effects on triglyceride levels and distinguish them from those with indirect effect, Figure 5. Using the underlying 
relationships between metabolites and triglycerides, we employed structural equation modeling and measured the causal 
effects. For more details see Supplementary, section 4. Nine metabolites were identified with direct effect on triglycerides 
at significance level 0.001; the estimated causal effects are presented in Supplementary, Table S2. The effect of the other 
metabolites to triglyceride levels is through the set of metabolites with direct effect on triglycerides. For the analysis, log 
transformation of triglyceride levels was adjusted for covariates including age and principle components for population 
stratification applying a linear regression. The analysis after including body mass index (BMI) in the set of covariates did 
not show significant effect of glutamate, glycine, and deoxycarnitine on triglyceride levels.   
The systems approach applied facilitates distinguishing between direct and indirect metabolite-triglyceride 
pathways. Some of the novel findings of this analysis have already been validated clinically (Yazdani et al., 2018). While 
through an association study 21 metabolites out of the 122 are found associated with triglyceride levels, applying the 
systems approach identified that only 6 of them (after adjustment for BMI) have direct effect on triglyceride levels. 
Therefore, the systems approach applied here provides efficacious targets for intervention compared to association studies. 
For the results of the association study, see Supplementary, Table S3.  
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Figure 5. Relationship among metabolites with direct effect on triglyceride levels. Arachidonic acid has the largest 
effect on triglycerides. No feed-back loop (i.e. cycles) was identified between these metabolites and 
triglyceride levels. The relationships among metabolites are identified from the genomic-metabolomic 
network depicted in the background to emphasize that the directions are identifies based on Mendelian 
principles.  
 
LoF mutation-metabolite pathway: LoF variants included in this study were defined as premature stop codons occurring 
in the exon, essential splice site disrupting, and indels predicted to disrupt the downstream reading frame. Seven genes 
with significant effect (P_val < 1.3 × 10−7) on metabolites in our analysis are integrated with the metabolomic network, 
Figure 6 and Supplementary, Table S4. For the analysis, single-variant tests for the single variants and gene-based burden 
tests for the genes were utilized 26 to investigate the relationship with the individual metabolites.  
 
Figure 6. Gene-metabolomic network. The genes harboring LoF mutations are depicted on the metabolomic network 
in red rectangular.  The strongest relationship is for LRRC69, which is depicted in a bigger size than the other genes.  
 
Identified genome-metabolite-triglyceride pathways  
Through combining the results of the three steps above, we identify pathways from the genome to plasma 
triglycerides via metabolomic network. By inspecting the metabolites with direct effect on triglyceride levels and those 
influenced by LoF mutations, we identified two direct pathways linking the genome to plasma triglycerides: One path 
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from LRRC46 through metabolite urate (LRRC46  Urate Triglycerides), and another path from LRRC69 through 
metabolite deoxycarnitine (LRRC69Deoxycarnitine  Triglycerides). These pathways are visualized in Figure 7.  
 
 
 
Figure 7. Two identified direct pathways from LRRC46 and LRRC96 to plasma triglycerides via metabolites 
urate and deoxycarnitine respectively. 
 
In Figure 8 below, blue pathways depict metabolites with influence on urate and deoxycarnitine. In the left panel, 
propionylcarnitine and isovalerate are lipids involved in fatty acid metabolism; docosahexaenoate is an essential fatty 
acid; glycine is an amino acid involved in glycine, serine, and threonine metabolism; and finally gamma-
glutamylthreonine is a peptide in gamma-glutamyl metabolism. In the right panel of Figure 8, 3-carboxy-4-methyl-5-
propyl-2-furanpropanoate, azelate, and laurate are fatty acids; citrate is a component of the tricarboxylic acid cycle that is 
central to energy metabolism; and trans-4-hydroxyproline is a modified amino acid associated with the urea cycle and is 
thought to be associated with oxidative stress.  
 
Figure 8. Red pathways: Direct pathways from the genome to triglycerides via urate and deoxycarnitine. Blue 
pathways: Metabolites that influence urate and deoxycarnitine at metabolomic network.  
 
In addition to the above direct pathways from the genome to triglycerides via metabolomics, two indirect 
pathways are identified to triglycerides. Genes FAM198B and C6orf25 influence metabolite HETE with indirect effect 
on triglyceride levels. These pathways are through metabolite palmitoylglycerophosphoinositol. In Figure 9, we see that 
the identified pathways to triglycerides is not through arachidonic acid. Rather, arachidonic acid influences this path 
through HETE. These results are identified using the metabolomic causal network. 
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Figure 9. Indirect pathways from FAM198B and C6orf25 to triglycerides through metabolite HETE and 
palmitoylglycerophosphoinositol. 
 
The identified pathways through the systems approach introduced here may facilitate understanding underlying 
mechanism and generate hypotheses for further experimental studies. Through a standard GWAS analysis, we 
investigated genome-triglyceride relationship and no variant with significant effect on triglyceride levels was identified. 
The results are provided in Supplementary, Table S5. 
 
Discussion  
The genetics of complex diseases, such as cardiovascular disease, produce alterations in the molecular interactions 
of intermediate phenotypes, such as metabolites, which contribute to early disease-related changes 27 28. The collective 
effect in cellular pathways may become clear through integrated approaches to identify underlying mechanisms. Powerful 
and advanced analytic strategies are required to integrate largescale data in systems biology for the elucidation of pathways 
across human biological levels. We introduced a systems approach for pathway identification by integrating data at three 
different biological levels using causal networks. Causal networks compatible with structural equation modeling improve 
the power of discovery by reducing the influence of phenotype-phenotype associations to illustrate underlying 
relationships 7 29. 
The introduced approach is toward mechanistic understanding through pathway identification linking the genome 
to health/disease. The pathways reveals the underlying relationships behind observations 303112, which do not play a 
significant role in more traditional correlative analyses. We first construct a causal network over metabolomics using 
IVs/Mendelian randomization 7. Through a metabolomic causal network, we not only account for association between 
metabolites but also confounders at metabolomics. Second, we take an improvement in understanding the role of 
metabolites in quantitative risk factors, here triglycerides  7. This step filters the number of metabolites to a subset that 
impact triglyceride levels. In addition, the visualization of underlying relationships reveals even more information. 
Through integration of the metabolomic causal network and genome association study, two pathways were 
identified, from the genome—leucine rich repeat containing 46, LRRC46, and leucine rich repeat containing 69, 
LRRC69—linked to plasma triglycerides via the metabolites urate and deoxycarnitine, respectively. Those metabolite-
triglyceride connections are consistent with known biochemical information. For example, urate is biochemically linked 
to the thioredoxin system, which mediates cellular redox balance and has been associated with triglyceride levels 32. 
Similarly, deoxycarnitine lies at a biochemical crossroad between triglyceride metabolism and fatty acid oxidation, and 
carnitine metabolism has been implicated in the regulation of triglycerides 33. Further, carnitine is essential for β-oxidation 
of long-chain fatty acids, and metabolic enzymes involved in carnitine biosynthesis mediate a decrease in fatty acid 
oxidation and increase in glycolysis in heart failure progression 34. 
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The genetic components LRRC46 and LRRC69 provide new mechanistic insights into the regulation of 
triglyceride levels. Experimental validation will need to be conducted to assess the contributions of LRRC46 and LRRC69 
to the modulation of triglyceride levels, but our new approach allows such validation experiments to be focused. For 
instance, instead of measuring only triglyceride levels as an endpoint in a model biological system, we can additionally 
measure levels of uric acid, deoxycarnitine, and other metabolites known to be associated with each of them, such as 
thioredoxins. For example, since thioredoxins have been found to mediate cardioprotection, it may be possible to implicate 
LRRC46 in cardioprotection upstream of thioredoxins regulation. 
The leucine-rich repeat (LRR) structural motif is characterized by the α/β horseshoe fold, composed of 20-30 
hydrophobic amino acid stretches of leucine. LRRs mediate protein-ligand interactions and in the case of cascade 
interaction model in fatty-acid-uremic toxin-drug system, in which long-chain fatty acids concentrations are increased, 
cascade displacement of bound drugs occurs by a competitive inhibitor, such as CMPF and uremic toxins containing an 
indole ring 35. Previous studies reveal a relationship between leucine-rich repeat (LRR) and cardiovascular disease and 
triglycerides 3637. The pathways identified here strengthen those associations and provide a plausible mechanism for them. 
The approach presented here provides a step toward addressing challenges in modern biomedical research, such 
as largescale data sets, highly correlated phenotypes, and integrating information at different biological levels. 
Additionally, future method development will include genome variation effects on multiple metabolites, hypothesized 
pleiotropy in GWAS/WGS, to provide further insights into the mechanistic underpinnings of chronic diseases.  
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1. Causal Inference in Observational Study 
In observational studies, where intervention is not possible, causal inference is derived by 
identifying the assignment mechanism (AM), i.e. causal relationships, underlying the 
observations (1)(2)(3)(4). The AM represents how different levels of a response variable are 
assigned and which covariates are involved. The illumination of the AM is carried out using 
knowledge about response variables (
RK ) and is required for any causal inference. This 
assumption is formalized by )( RKAM and is called causal parameter (4). Any causal quantity 
is implicitly or explicitly conditioned on the causal parameter )( RKAM . The causal parameter 
represents the necessity of illumination of the AM by
RK . 
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In this study, the AM is illuminated by the fact that inherited genomic variation is a causal 
factor for variations in the metabolomics level (an upper granularity) and not the other way 
around. This is the applied knowledge about metabolite response variables (
RK ) to illuminate 
the AM. The AM or underlying relationship is estimated using different approaches, such as 
propensity score, Matching, or causal networks. Here, we utilize causal networks and 
illuminate the AM by a directed acyclic graph (3). We then graphically identify confounders 
among covariates to measure causal effect sizes. For the definition of confounders and 
covariates see (5). 
This section is published previously as supplementary of (6). It is provided here for the 
readers’ convenience.  
 
 
2. The G-DAG algorithm  
First, there is a reduction in the number of SNPs using hierarchical clustering and the square 
of the correlation measure of linkage disequilibrium, e.g. see (7). Second, the genomic 
information was summarized using the set of principal components applied to each 
chromosome to create IVs. Third, the set of IVs responsible for >80% of the variation over 
each chromosome was selected. Fourth, the G-DAG algorithm determines genome-wide IVs 
that are significantly related to each metabolite excluding the effect of other metabolites and 
IVs in the model. Fifth, The G-DAG algorithm dentifies a topology over metabolomics, an 
undirected metabolomics Bayesian network determined through metabolite analysis. Sixth, 
using the IVs and Bayesian rules, the G-DAG algorithm determines directions over the 
metabolomic topology. The analysis can be carried out either in a constraint-based or score-
based framework. We have implemented the G-DAG algorithm in a constraint-based 
framework (8). Note that in the G-DAG algorithm, using the same data twice is avoided since 
unsupervised statistical methods are employed to extract information from the genotype data. 
The causal network is a representation of following properties (Metabo paper): 
 
))(,(| RMri KAMSMM i , for iMr SM  ,          (1) 
where mjM j ,...,1,   stands for a metabolite in the system and m is the number of 
metabolites. 
iM
S includes metabolites with an arrow in node iM  in the network and )( RKAM  
stands for causal parameter (4). Representation of underlying relationships is a representation 
of Assignment Mechanism (AM) which can be illuminated using Knowledge about Response 
(
RK ). Conditioning the properties (1) on the causal parameter )( RKAM  explicitly represent 
that underlying relationships are taken into account to analyze data in a causal setting.   
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3. Features of the G-DAG algorithm 
The G-DAG algorithm utilizes principal component analysis to extract near-complete 
information from across the genome and create strong and independent IVs. Principal 
components are powerful in capturing the effect of multiple loci (9).  
Each of the IVs includes information from several SNPs/genes across the genome, therefore, 
they are much stronger than a single gene. Since information from each SNP is extracted, the 
G-DAG algorithm is able to create several hundreds strong instrumental variables and identify 
directions robustly over a metabolomics topology in large scale. The G-DAG algorithm takes 
the following steps to hold the underlying assumptions of Mendelian 
randomization/instrumental variable approach through following features:  
1) Creating and employing strong instrumental variables through extracting information 
from multiple    Variants across the genome; 
2) Creating independent instrumental variables toward holding the assumption of 
validity; 
3) Multiple independent instrumental variables for each metabolite, to make overall IVs 
even stronger.  
Employed instrumental variables explain a majority of variations in each metabolite, even up 
to 96%. Since a majority of variations in each metabolite is explained by instrumental 
variables, the identified directions are robust (15). Utilizing independent IVs is toward 
overcoming pleiotropic effect of SNPs, LD structure, and even gene-gene interactions. 
4. Causal effect measurement  
We measured the effect of each metabolite on baseline triglyceride levels given the overall 
metabolomic-triglecerides network by  
UMKAMRF i
Si
iR
RF
 

)(|  
where iM  stands for ith metabolite and RFS stands for a set of metabolites with direct effect 
on RF. The  RF corresponds the risk factor triglyceride levels. U stands for all factors with 
effect on RF but independent from iM  and )( RKAM  stands for the causal parameter and 
conditioning on the causal parameter is corresponding to illuminating the assignment 
mechanism (AM)/causal relationships behind observations by gathering knowledge about 
response, here RF. By illumination of the AM through causal ntworks, we can identify 
confounders at the metabolomic level and consider them in the model to assume
iMU  , see 
graphical criteria in (3). As a result, we can estimate the effect of a specific metabolite on 
triglyceride levels, and the coefficients i have causal interpretations. Note that equations 
written based on causal networks are called structural equation models. In other word, causal 
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networks and structural equation modelings are compatible (3). For more details of causal 
effect measurement see (10) (11). A version of this section is published as supplementary in 
(6). 
 
5. Materials and data measurments 
Study Population:  The Atherosclerosis Risk in Communities (ARIC) study is a prospective 
epidemiological study designed to investigate the etiology and predictors of cardiovascular 
disease (CVD). The ARIC study enrolled 15,792 individuals aged 45-64 years from four U.S. 
communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and 
Washington County, MD) in 1987-89 (baseline) and followed for four completed visits in 
1990-92, 1993-95, 1996-98 and 2011-13. A detailed description of the ARIC study design and 
methods is published elsewhere (12). Basic cardiovascular disease risk factors were measured 
at each visit, and cardiovascular disease endpoints, including heart failure, were ascertained 
annually using telephone interviews and hospital medical record review. In ARIC, incident 
heart failure (HF) was defined as the first hospitalization or death from HF for those without 
a prior HF hospitalization. The diagnosis of HF was based on International Classification of 
Diseases, Ninth Revision (ICD-9) code 428.3.  Individuals were followed up for events from 
baseline through December 31, 2011; and those who were lost to follow-up were censored at 
the date of last contact. Incident type 2 diabetes was defined in diabetes free participants at 
baseline and having a follow-up visit until visit 4 with either: (i) a fasting glucose ≥7.0 mmol/L, 
(ii) a non-fasting glucose ≥11.1 mmol/L, (iii) use of a diabetes medication, or (iv) self-reported 
physician diagnosis. 
Metabolome Measurements: Metabolite profiling was measured using fasting serum 
samples collected at the baseline examination in 1987-1989 among ARIC European- and 
African-Americans. For the discovery African-American samples, a total of 602 metabolites 
were detected and quantified by Metabolon Inc. (Durham, USA) using an untargeted, gas 
chromatography-mass spectrometry and liquid chromatography-mass spectrometry (GC-MS 
and LC-MS)-based metabolomic quantification protocol (2, 3). Detection of metabolites were 
completed in June 2010. Metabolites were excluded if: i) Missing values more than 50% of 
the samples, ii) Unknown chemical structures, and iii) Not following normal distribution. 
After these assessments, a total of 122 metabolites were included in the present study. 
Replication samples were utilized to identify an optimal approach for imputation which was 
KNN. Therefore, missing values were imputed by KNN algorithm. Metabolite levels were 
transformed to normal with different transformation (not necessary log-transformation) prior 
to the analyses.  
Whole Exome Sequencing: The annotated exome was captured by Nimblegen’s VCRome2.1 
(Roche NimbleGen, Madison, WI, USA) and the captured exons were sequenced using 
Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). The Burrows–Wheeler Aligner was 
used to align sequence to the hg19 reference genome (13). Allele calling and variant call file 
(VCF) construction was performed using the Atlas2 suite (14) (Atlas-SNP and Atlas-Indel). 
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Single nucleotide variants were excluded if they had a posterior probability less than 0.95, 
total depth of coverage less than 6x, allelic fraction < 0.1, 99% of reads in a single direction 
and homozygous reference alleles with < 6x coverage.  Low-quality indels were excluded if 
they had minimum total depth < 30, allelic fraction < 0.2 for heterozygous variants and < 0.8 
for homozygous variants and variant reads < 10x.  Following statistical analysis, all 
significantly associated variants were validated using an orthogonal laboratory technology 
(i.e. Array-based genotyping, Sequenome genotyping, or Sanger sequencing). All reported 
results were validated with 100% accuracy.  
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Figure A1. Distribution of the number of LoF variants per individual in ARIC African-
American population.  
 
Mean values ± standard deviations for continuous variables.  
 
Table S1. Baseline Characteristics of African Americans in ARIC with metabolomic and exome 
sequence  
                 data. 
Characteristic  N = 1,361 
Age, years 52.5 ± 5.6 
Male, n (%) 464 (34.1) 
Body mass index, kg/m2 29.8 ± 6.2 
Hypertension, n (%) 705 (51.8) 
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Diabetes, n (%) 190 (14.0) 
Prevalent coronary heart disease, n 
(%) 
49 (3.6) 
Current smoker, n (%) 377 (27.7) 
Systolic blood pressure, mm Hg 126.9 ± 19.0 
Diastolic blood pressure, mm Hg 80.2 ± 11.4 
HDL cholesterol, mg/dL 56.1 ± 17.4 
LDL cholesterol, mg/dL 135.2 ± 38.0 
Triglycerides, mg/dL 106.2 ± 55.9 
Total cholesterol, mg/dL 212.5 ± 40.0 
 
Table S2. The causal network parameters and the effect sizes of nine metabolites 
with direct    
                 effect on plasma triglycerides.  
 
a. Effect sizes measured in standard deviation units to facilitate comparison. 
b. Metabolite with no significant effect at level 0.0001 after adjustment for BMI 
 
 
The analysis after including body mass index (BMI) in the set of covariates did not show 
significant effect of glutamate, glycine, and deoxycarnitine on triglyceride levels, which are 
noted with superscript “b” in Table S2.   
More information can be obtained from further analysis of metabolomic network called causal 
parameters(15). In Table S2, in addition to p-value and effect size, three causal network 
parameters Out-degree, In-degree, and Strength are presented to investigate potential roles of 
the metabolites.  
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- In-degree represents the number of metabolites that influence a particular metabolite. At the 
metabolomic causal network the In-degree parameter has a range from 0 to 9. Metabolites 
with higher In-degree capture features of higher number of metabolites in the metabolomic 
network. 
- Out-degree represents the number of metabolites influenced by a particular metabolite. At 
the metabolomic causal network the Out-degree parameter has a range from 0 to 8 at the 
metabolomic causal network. Metabolites with higher Out-degree influence higher number of 
metabolite in the network.  
- Strength represents how strong a metabolite is connected to the network, ranges from 0 to 
50 at the metabolomic causal network. The Strength zero (the lowest strength) means the 
metabolite is not connected to the network.  
In comparison to the range of Out-degree in the metabolomic network (0 to 8), the study 
reveals that the metabolites with direct effect on triglycerides have very low Out-degree, 
which is corresponding to their low influence in metabolomic network.   
 
There are other approaches for pattern recognition that can be brought in the biomedical 
research such a (16) (17)(18)(19)(20). These approaches can improve pattern identification 
among highly correlated traits at each omic.  
 
Table S3. Assocciated metabolites with triglycerides at significance level 4e-4 (Bonferroni 
correction of 122 test for 122 metabolites) which carried out via linear regression. 
ID Metabolite          p-value 
1 arachidonate 4.29E-26 
2 dihomolinolenate 1.66E-12 
3 carnitine 1.30E-11 
4 urate 4.86E-10 
5 docosahexaenoate 6.72E-10 
6 isoleucine 7.65E-10 
7 palmitoylglycerophosphoinositol 4.83E-09 
8 leucine 1.11E-08 
9 adrenate 5.32E-08 
10 9HODE 5.94E-08 
11 eicosapentaenoate 1.25E-07 
12 isovalerate 7.15E-07 
13 valine 1.14E-06 
14 arachidonoylglycerophosphoinositol 2.29E-06 
15 isovalerylcarnitine 1.16E-05 
16 phenylalanine 8.79E-05 
17 glycerol 9.81E-05 
18 propionylcarnitine 0.000181773 
19 kynurenine 0.000247776 
20 glycine 0.000257107 
21 glutamate 0.0004107 
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Table S4. Genes harboring LoF mutation with significant effect on individual 
metabolites under study. The causal network parameters are measured from the 
metabolomic causal network. Variant includes chromosome:position:reference 
allele:alternative allele. 
 
 
LoF variants included in this study were defined as premature stop codons occurring in the 
exon, essential splice site disrupting, and indels predicted to disrupt the downstream reading 
frame. 
Potential roles of these metabolites in the metabolomic system are investigated through 
causal network parameters. The metabolites influenced by LoF mutations tabulated in Table 
2 do not have important roles at the metabolomic network due to low number of Out-degrees 
and relatively higher number of In-degree. Later, we see both metabolites urate and 
deoxycarnitine are in direct paths to triglycerides, Figure 7. Interestingly, both of them have 
a high In-degree and zero Out-degree. We conclude the metabolites influenced by LoF 
mutations are mostly influenced by metabolomic system rather than influence the system. 
This may be interpreted as below: metabolites influences by LoF mutations cannot be so 
critical at metabolomics. Otherwise they will lead to debilitating disease or be inconsistent 
with life. This point can be considered and discussed for functional understanding although 
it may require further assessments.  
 
Table S5: Six top lowest p-value from genome-triglyceride analysis. Triglycerides is adjusted 
for BMI. No variant with a significant effect on triglyceride levels is identified.  
SNP Estimate Std. Error t-value p-value 
X9.21481483.G.A 0.184157 0.061768 2.981432 0.002903 
X13.111367876.G.C 0.195495 0.067422 2.899555 0.003777 
X17.67149973.G.A 0.168886 0.060432 2.794665 0.005244 
X9.73152037.C.T 0.925106 0.376876 2.454672 0.014184 
X16.90128376.G.A 0.252941 0.116398 2.173062  0.02989 
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X3.148559694.C.T 0.539245   0.27711 1.945963  0.051796 
 
Table S6. The super‐pathway, sub-pathway, and measurement platform for 122 metabolites 
measured in African-Americans population in ARIC study. 
BIOCHEMICAL SUPER_ 
PATHWAY 
SUB_ 
PATHWAY 
 PLATFORM 
Glutarate Amino acid Lysine metabolism GC/MS 
p-cresol sulfate Amino acid Phenylalanine & tyrosine metabolism LC/MS 
neg 
Leucine Amino acid Valine, leucine and isoleucine 
metabolism 
LC/MS 
pos 
Isoleucine Amino acid Valine, leucine and isoleucine 
metabolism 
LC/MS 
pos 
Valine Amino acid Valine, leucine and isoleucine 
metabolism 
LC/MS 
pos 
gamma-glutamylalanine Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylglutamate Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylisoleucine Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylleucine Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylphenylalanine Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylthreonine Peptide gamma-glutamyl LC/MS 
pos 
gamma-glutamylvaline Peptide gamma-glutamyl LC/MS 
pos 
Glycylleucine Peptide Dipeptide LC/MS 
pos 
Leucylalanine Peptide Dipeptide LC/MS 
pos 
Serylleucine Peptide Dipeptide 
 
Caproate Lipid Medium chain fatty acid LC/MS 
neg 
Myristate Lipid Long chain fatty acid LC/MS 
neg 
Myristoleate Lipid Long chain fatty acid LC/MS 
neg 
Palmitate Lipid Long chain fatty acid LC/MS 
neg 
Palmitoleate Lipid Long chain fatty acid LC/MS 
neg 
Margarate Lipid Long chain fatty acid LC/MS 
neg 
heptadecanoate Lipid Long chain fatty acid LC/MS 
neg 
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stearate180 Lipid Long chain fatty acid LC/MS 
neg 
oleate181n9 Lipid Long chain fatty acid GC/MS 
Nonadecenoate Lipid Long chain fatty acid LC/MS 
neg 
Eicosenoate Lipid Long chain fatty acid LC/MS 
neg 
Linoleate Lipid Long chain fatty acid LC/MS 
neg 
Linolenate Lipid Long chain fatty acid LC/MS 
neg 
dihomo-linoleate Lipid Long chain fatty acid LC/MS 
neg 
Adipate Lipid Fatty acid, dicarboxylate GC/MS 
Azelate Lipid Fatty acid, dicarboxylate LC/MS 
neg 
sebacate Lipid Fatty acid, dicarboxylate LC/MS 
neg 
dodecanedioate Lipid Fatty acid, dicarboxylate LC/MS 
neg 
octanoylcarnitine Lipid Carnitine metabolism LC/MS 
pos 
decanoylcarnitine Lipid Carnitine metabolism LC/MS 
pos 
cis4decenoylcarnitine Lipid Carnitine metabolism LC/MS 
pos 
laurylcarnitine Lipid Carnitine metabolism LC/MS 
pos 
hydroxypalmitate2 Lipid Fatty acid, monohydroxy LC/MS 
neg 
hydroxystearate Lipid Fatty acid, monohydroxy LC/MS 
neg 
9-HODE Lipid Fatty acid, monohydroxy LC/MS 
neg 
Choline Lipid Glycerolipid metabolism LC/MS 
pos 
Arachidonoylglycerophosphoch
oline 
Lipid Lysolipid LC/MS 
neg 
docosapentaenoyl 
glycerophosphocholine 
Lipid Lysolipid LC/MS 
pos 
docosahexaenoylglycerophosph
ocholine 
Lipid Lysolipid LC/MS 
pos 
hydroxypregnenolonedisulfate Lipid Sterol/Steroid LC/MS 
neg 
pregnsteroidmonosulfate Lipid Sterol/Steroid LC/MS 
neg 
androsten3beta17betadioldisulf
ate2 
Lipid Sterol/Steroid LC/MS 
neg 
erythritol Xenobiotics Sugar, sugar substitute, starch GC/MS 
Glycine Amino acid Glycine, serine and threonine metabolism GC/MS 
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Betaine Amino acid Glycine, serine and threonine metabolism LC/MS 
pos 
Serine Amino acid Glycine, serine and threonine metabolism GC/MS 
threonine Amino acid Glycine, serine and threonine metabolism LC/MS 
pos 
Alanine Amino acid Alanine and aspartate metabolism GC/MS 
N-acetylalanine Amino acid Alanine and aspartate metabolism LC/MS 
neg 
glutamate Amino acid Glutamate metabolism LC/MS 
neg 
pyroglutamine Amino acid Glutamate metabolism LC/MS 
pos 
Lysine Amino acid Lysine metabolism LC/MS 
pos 
glutaryl carnitine Amino acid Lysine metabolism LC/MS 
pos 
phenylalanine Amino acid Phenylalanine & tyrosine metabolism LC/MS 
pos 
phenylacetylglutamine Amino acid Phenylalanine & tyrosine metabolism LC/MS 
pos 
tyrosine Amino acid Phenylalanine & tyrosine metabolism LC/MS 
pos 
hydroxyphenyllactate Amino acid Phenylalanine & tyrosine metabolism GC/MS 
tryptophan Amino acid Tryptophan metabolism LC/MS 
pos 
kynurenine Amino acid Tryptophan metabolism LC/MS 
pos 
isovalerate Lipid Fatty acid metabolism LC/MS 
neg 
isovalerylcarnitine Amino acid Valine, leucine and isoleucine 
metabolism 
LC/MS 
pos 
isobutyrylcarnitine Amino acid Valine, leucine and isoleucine 
metabolism 
LC/MS 
pos 
methioninesulfoxide Amino acid Cysteine, methionine, SAM, taurine 
metabolism 
LC/MS 
pos 
aminobutyrate Amino acid Butanoate metabolism LC/MS 
pos 
hydroxybutyrate2 Amino acid Cysteine, methionine, SAM, taurine 
metabolism 
GC/MS 
Urea Amino acid Urea cycle; arginine-, proline-, 
metabolism 
GC/MS 
Proline Amino acid Urea cycle; arginine-, proline-, 
metabolism 
LC/MS 
pos 
trans-4-hydroxyproline Amino acid Urea cycle; arginine-, proline-, 
metabolism 
LC/MS 
pos 
guanidinobutanoate Amino acid Guanidino and acetamido metabolism LC/MS 
pos 
oxoproline Amino acid Glutathione metabolism LC/MS 
neg 
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gammaglutamyltyrosine Peptide gamma-glutamyl LC/MS 
pos 
glycylvaline Peptide Dipeptide LC/MS 
pos 
Lactate Carbohydrate Glycolysis, gluconeogenesis, pyruvate 
metabolism 
GC/MS 
mannose Carbohydrate Fructose, mannose, galactose, starch, and 
sucrose metabolism 
GC/MS 
Citrate Energy Krebs cycle GC/MS 
succinate Energy Krebs cycle LC/MS 
neg 
phosphate Energy Oxidative phosphorylation GC/MS 
heptanoate Lipid Medium chain fatty acid LC/MS 
neg 
Laurate Lipid Medium chain fatty acid LC/MS 
neg 
nonadecanoate Lipid Long chain fatty acid LC/MS 
neg 
eicosapentaenoate Lipid Essential fatty acid LC/MS 
neg 
docosahexaenoate Lipid Essential fatty acid LC/MS 
neg 
dihomolinolenate 
   
arachidonate Lipid Long chain fatty acid LC/MS 
neg 
adrenate Lipid Long chain fatty acid LC/MS 
neg 
carboxy4methyl5propyl2furanp
ropanoate 
Lipid Fatty acid, dicarboxylate LC/MS 
neg 
propionylcarnitine Lipid Fatty acid metabolism (also BCAA 
metabolism) 
LC/MS 
pos 
deoxycarnitine Lipid Carnitine metabolism LC/MS 
pos 
carnitine Lipid Carnitine metabolism LC/MS 
pos 
HETE Lipid Fatty acid, monohydroxy LC/MS 
neg 
myoinositol Lipid Lysolipid 
 
glycerophosphorylcholine Lipid Glycerolipid metabolism LC/MS 
pos 
Palmitoleoylglycerophosphochol
ine 
Lipid Lysolipid LC/MS 
pos 
oleoylglycerophosphocholine Lipid Lysolipid LC/MS 
pos 
Palmitoylplasmenylethanolamin
e 
Lipid Lysolipid LC/MS 
pos 
Palmitoylglycerophosphoinosito
l 
Lipid Lysolipid LC/MS 
neg 
Arachidonoylglycerophosphoin
ositol 
Lipid Lysolipid LC/MS 
neg 
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glycerol Lipid Glycerolipid metabolism GC/MS 
glycerol3phosphate Lipid Glycerolipid metabolism GC/MS 
cholesterol Lipid Sterol/Steroid GC/MS 
pregnendioldisulfate Lipid Sterol/Steroid LC/MS 
neg 
Cortisol Lipid Sterol/Steroid LC/MS 
pos 
androsten3beta17betadioldisulf
ate1 
Lipid Sterol/Steroid LC/MS 
neg 
glycocholenate sulfate Lipid Bile acid metabolism LC/MS 
neg 
xanthine Nucleotide Purine metabolism, 
(hypo)xanthine/inosine containing 
LC/MS 
pos 
Urate Nucleotide Purine metabolism, urate metabolism LC/MS 
neg 
Uridine Nucleotide Pyrimidine metabolism, uracil containing LC/MS 
neg 
pseudouridine Nucleotide Pyrimidine metabolism, uracil containing LC/MS 
pos 
catecholsulfate Xenobiotics Benzoate metabolism LC/MS 
neg 
hippurate Xenobiotics Benzoate metabolism LC/MS 
neg 
    
 
 
 
